At what age can Augmentin (amoxicillin/clavulanate) be started in pediatric patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 5, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Age for Starting Augmentin (Amoxicillin/Clavulanate) in Pediatric Patients

Augmentin can be started at 3 months (12 weeks) of age for most pediatric infections, with special dosing considerations for infants younger than 3 months. 1

Age-Specific Dosing Guidelines

Infants Under 3 Months (Less than 12 Weeks)

  • For infants less than 12 weeks of age, the maximum recommended dose is 30 mg/kg/day of the amoxicillin component divided every 12 hours due to incompletely developed renal function affecting drug elimination. 1
  • The FDA label specifically addresses this age group with modified dosing to account for delayed amoxicillin elimination, though clavulanate elimination remains unaltered. 2
  • Treatment duration should be at least 10 days for infections caused by Streptococcus pyogenes to prevent acute rheumatic fever, even in this youngest age group. 1

Infants 3 Months and Older

  • Standard weight-based dosing can be used starting at 3 months of age, with doses ranging from 20-90 mg/kg/day of the amoxicillin component depending on infection severity and risk factors. 1
  • For infants 3-12 months with acute otitis media, the age-based oral suspension dosing is 2.5 ml three times daily of the 125/31 suspension. 3
  • The high-dose formulation (90 mg/kg/day amoxicillin with 6.4 mg/kg/day clavulanate in two divided doses) is particularly important for infants under 2 years, as this age group has increased risk for resistant organisms. 3

Clinical Pharmacology Supporting Early Use

  • Pharmacokinetic studies demonstrate that a syrup formulation of amoxicillin/clavulanate at 25 mg/kg doses (20 mg amoxicillin + 5 mg clavulanate per kg) achieves adequate plasma concentrations in children as young as 3 years, with mean peak levels of 7.2 mg/L for amoxicillin and 2.0 mg/L for clavulanic acid. 4
  • A pediatric formulation containing 100 mg amoxicillin and 12.5 mg clavulanic acid per ml has been studied in infants as young as 3 months for acute otitis media, demonstrating over 92% resolution rates. 5
  • The safety and effectiveness of amoxicillin/clavulanate has been established in pediatric patients through studies in children aged 2 months to 12 years with acute otitis media. 2

Critical Considerations for Neonates and Young Infants

  • There are currently no dosing recommendations for pediatric patients with impaired renal function under 3 months of age, requiring careful clinical judgment. 1
  • The 30 mg/kg/day maximum for infants under 12 weeks represents a significant dose reduction compared to older children (who may receive up to 90 mg/kg/day), reflecting the immature renal clearance in this population. 1
  • Amoxicillin is excreted in human milk, and use by nursing mothers may lead to sensitization of infants, requiring caution when administered to breastfeeding women with very young infants. 2

Common Pitfalls to Avoid

  • Do not use the 875 mg tablet formulation or high adult doses in young children—always use weight-based pediatric dosing with appropriate suspension formulations. 1
  • Verify the suspension concentration (125/31 vs 250/62 mg per 5 ml) before calculating volume to avoid dosing errors, as different concentrations require different volumes for the same dose. 3
  • The twice-daily high-dose formulation (90/6.4 mg/kg/day) causes less diarrhea than three-times-daily standard formulations while maintaining equivalent efficacy, making it preferable when high-dose therapy is indicated. 3, 6

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.